Behavioral health company Acadia Healthcare (NASDAQ: ACHC) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.4% year on year to $851.6 million. On the other hand, the company’s full-year revenue guidance of $3.29 billion at the midpoint came in 0.7% below analysts’ estimates. Its non-GAAP profit of $0.72 per share was 9.1% above analysts’ consensus estimates.

Is now the time to buy ACHC? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Acadia Healthcare’s third quarter results were marked by a negative market reaction, as management pointed to ongoing Medicaid-related volume and reimbursement pressures. CEO Christopher Hunter cited softer-than-expected volumes in the company’s Medicaid book of business, especially in acute care, as a key factor. The company also faced rising employee health costs and increased professional and general liability expenses, leading to a notable reduction in operating margin. Management acknowledged these headwinds, describing the quarter’s performance as impacted by “incremental headwinds from rates and benefit expense related to employee health care costs.”

Looking ahead, Acadia Healthcare’s revised guidance is influenced by continued payer friction in Medicaid, incremental cost pressures, and a more cautious approach to capital deployment. Management described a strategic focus on optimizing growth investments, scaling back capital expenditures, and closing underperforming facilities in response to the uncertain funding environment. CFO Todd Young highlighted that while startup losses and legal expenses are expected to step down, the reimbursement landscape remains challenging, especially as government payers face significant cost pressures. Hunter emphasized, “We are taking a more measured approach to capital deployment in the near term.”

Key Insights from Management’s Remarks

Management attributed the quarter’s results to Medicaid volume softness, payer reimbursement pressures, and increased liability costs, prompting a reduction in capital spending and targeted facility closures.

• Medicaid volume pressure: Acute care volumes were softer than anticipated, with Medicaid managed care plans increasing utilization review scrutiny, particularly impacting length of stay and reimbursement for patient care.
• Facility optimization actions: Five facilities—primarily underperforming or not aligned with strategic priorities—were closed, including acute and specialty units, as well as certain eating disorder centers, to focus resources on higher-return markets.
• Capital discipline shift: Management undertook a comprehensive review of development projects, pausing or canceling those that did not meet return thresholds, resulting in a planned $300 million reduction in capital expenditures for next year.
• Bed expansion and partnerships: Over 1,700 beds were added across 2024 and 2025, with an additional 500–700 beds expected next year, supported by new joint venture hospitals, enhancing capacity despite the CapEx pullback.
• Investments in quality and technology: Continued focus on standardized clinical protocols, real-time quality dashboards, and outcome tracking are intended to demonstrate value to payers and accrediting agencies, with management citing improved patient outcomes and staff retention as evidence of progress.

Drivers of Future Performance

Acadia Healthcare expects ongoing Medicaid reimbursement pressures, operational cost challenges, and disciplined capital allocation to shape its near-term performance.

• Continued Medicaid headwinds: Management flagged persistent challenges in Medicaid volumes and reimbursement, especially in select markets, with payer-related friction projected to remain a significant headwind for both revenue and profitability.
• Reduced capital spending and facility closures: The company’s shift toward capital efficiency includes a major reduction in development spending and a focus on optimizing the existing facility portfolio, which is expected to modestly improve margins and enable positive adjusted free cash flow in the next year.
• Ramp from new capacity and supplemental payments: Recent and upcoming bed additions, particularly through joint ventures, are expected to contribute to volume growth, while potential supplemental Medicaid payments—pending regulatory approval—could provide incremental EBITDA upside, though timing remains uncertain.

Catalysts in Upcoming Quarters

In the coming quarters, StockStory analysts will track (1) the pace at which new bed capacity drives volume and margin recovery, (2) the impact of Medicaid reimbursement negotiations and the approval of supplemental payment programs, and (3) evidence that capital allocation discipline is translating into improved free cash flow and profitability. Ongoing progress in leveraging technology for care quality and payer engagement will also be important to monitor.

Acadia Healthcare currently trades at $19.90, down from $20.68 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free for active Edge members).

Stocks That Trumped Tariffs

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.